Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Multicenter Study Comparing 6xFEC With 3xFEC-3xDoc in High-risk Node-negative Patients With Operable Breast Cancer: Comparison of Efficacy and Evaluation of Clinico-pathological and Biochemical Markers as Risk Selection Criteria
Brief Summary: In low-risk node-negative breast cancer patients adjuvant chemotherapy should be spared. The identification of this subgroup can be based either on clinical and pathological or on tumour-biological criteria. Due to their high prognostic impact, the tumour-biological invasion markers uPA/PAI-1 (urokinase-type plasminogen activator and its inhibitor PAI-1) are potential candidates to effectively assess the risk of relapse in node-negative breast cancer. This study is aimed to compare the risk assessment by the traditional clinico-pathological factors and by tumour-biological factors. The second study question refers to the comparison between an adjuvant combination treatment with FE100C\*6 and a sequential treatment with FE100C\*3 and Docetaxel\*3.


Options:
A: Arm Label: TAC (Docetaxel); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Doxorubicin, Drug: Cyclophosphamide | Arm Label: FAC (5-fluorouracil); Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-fluorouracil, Drug: Doxorubicin, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): TAC (Docetaxel) | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): FAC (5-fluorouracil) | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): FAC (5-fluorouracil), TAC (Docetaxel) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): FAC (5-fluorouracil), TAC (Docetaxel)
B: Arm Label: Arm I (CA for 4 courses); Type: ACTIVE_COMPARATOR; Interventions: Drug: AC regimen, Drug: doxorubicin hydrochloride | Arm Label: Arm II (CA for 6 courses [closed to accrual 12/15/2007]); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride | Arm Label: Arm III (paclitaxel for 4 courses); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: paclitaxel | Arm Label: Arm IV (paclitaxel for 6 courses [closed 12/15/2007]); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: paclitaxel | Intervention Type: DRUG; Name: AC regimen; Assigned to Arm(s): Arm I (CA for 4 courses), Arm II (CA for 6 courses [closed to accrual 12/15/2007]), Arm III (paclitaxel for 4 courses), Arm IV (paclitaxel for 6 courses [closed 12/15/2007]) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm II (CA for 6 courses [closed to accrual 12/15/2007]) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (CA for 4 courses), Arm II (CA for 6 courses [closed to accrual 12/15/2007]) | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Arm III (paclitaxel for 4 courses), Arm IV (paclitaxel for 6 courses [closed 12/15/2007])
C: Arm Label: Arm A Taxane-containing; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Arm B standard anthracyclin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel; Assigned to Arm(s): Arm A Taxane-containing, Arm B standard anthracyclin
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: methotrexate, Drug: 5-fluorouracil | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: docetaxel | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): B | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): A

Answer: C